top of page
Decoding Neurological Disease. Advancing Precision Medicines.
CELLTIUM is developing precision therapies for CMT1A and peripheral neuropathies. By combining deep disease biology with our proprietary PRECISION™ platform, we are accelerating the translation of scientific discovery into disease-modifying therapies.
A New Neurotherapeutics Model
Our approach is built on an integrated discovery engine that combines quantitative phenotyping, multimodal data, and AI/ML. From the outset, this framework supports target identification, lead optimization, and data-driven decision-making.
Targeting Core Disease Biology
We are advancing a precision pipeline of differentiated small-molecule programs to address the underlying biology of peripheral neuropathies. Beyond symptom management, our goal is to restore nerve function and meaningfully alter the course of disease.
Partner With Us
We welcome strategic collaborations with investors, biopharma partners, and patient advocacy organizations to advance our lead CMT1A program into the clinic and broaden the reach of our PRECISION™ platform across rare neurology indications.
bottom of page